Inflammation and alzheimer’s disease: Mechanisms and therapeutic strategies

Gerontology

Volumn 43, Issue 1-2, 1997, Pages 143-149

  Aisen, Paul S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer s disease; Anti inflammmatory drugs; Glucocorticoids; Inflammation; Therapeutics

Indexed keywords

ANTIINFLAMMATORY AGENT; COLCHICINE; COMPLEMENT; CYTOKINE; HYDROXYCHLOROQUINE; PREDNISONE;

ACUTE PHASE RESPONSE; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; ENCEPHALITIS; HUMAN; MICROGLIA; MULTICENTER STUDY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; HUMANS; INFLAMMATION;

EID: 0031031312     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000213842     Document Type: Article

References (63)

1. Zhan SS, Veerhuis R, Kamphorst W, Eikclenboom P: Distribution of beta amyloid associated proteins in plaques in Alzheimer’s disease and in the non-dcmented elderly. Neurodegeneration 1995;4:291-297.
2. Bauer J, Strauss S, Schrciter-Gasscr U, Gamer U, Schlegel P, Witt I, Yolk B, Berger M: Interlcukin-6 and alpha-2-macroglobulin indicate an acute phase response in Alzheimer's disease cortices. FEBS Lett 1991; 285:111-114.
3. Vandenabeele P, Fiers W: Isamyloi-dogencsis during Alzheimer’s disease due to an IL-l/lL-6-mcdiatcd ‘acute phase response’ in the brain? Immunol Today 1991;12:217-219.
4. Griffin WS, Stanleyx LC, Ling C, White L, Macleod V, Perrot LJ, White CL, Araoz C: Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989;86:7611-7615.
5. Bauer J, Ganter U, Strauss S, Stadt mtiller G, Frommbcrger U, Bauer H, Volk B, Berger M: The participation of intcrleukin-6 in the pathogenesis of Alzheimer’s disease. Res Immunol 1992,143:650-657.
6. Griffin WS, Shcng JG, Roberts GW, Mrak RE: Interlcukin-1 expression in different plaque types in Alzheimer’s diseases: Significance in plaque evolution. J Neuropathol Exp Neurol 1995;54:276-281.
7. Sheng JG, Mrak RE, Griffin WST: Microglial interleukin-la expression in brain regions in Alzheimer’s disease: Correlation with neuritic plaque distribution. Neuropathol Appi Neurobiol 1995;21:290-301.
8. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MBA, Mucke L: Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA 1993,90: 10061-10065.
9. Blume AJ, Vitek MP: Focusing on IL-1 promotion of beta-amyloid precursor protein synthesis as an early event in Alzheimer’s disease. Neurobiol Aging 1989;10:406-408.
10. Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffc EA, Gandy SE, Greengard P: Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer ß/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992;89:10075-10078.
11. Dash PK, Moore AN: Enhanced processing of APP induced by IL-1 ß can be reduced by indomcthacin and norhydroguaiarctic acid. Bio-chem Biophys Res Commun 1995; 208:542-548.
12. Rogers J, Schultz J, Brachova L, Lue L-F, Webster S, Bradt B, Cooper NR, Moss DE: Complement activation and ß-amyloid-mediated neurotoxicity in Alzheimer’s disease. Res Immunol 1992:143:624-630.
13. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I: Complement activation by ß-amyloid in Alzheimer disease. Proc Natl Acad Sei USA 1992;89:10016-10020.
14. McGccr PL, Akiyama H, Itagaki S, McGeer EG: Immune system response in Alzheimer’s disease. Can J Neurol Sei 1989:16:516-527.
15. Ishii T, Haga S, Kamctani F: Presence of immunoglobulins and complements in the brain of patients with Alzheimer's disease: in Pou-plard-Barthclaix A, Emile J, Christen Y (eds): Immunology and Alzheimer’s Disease. Berlin, Springer. 1988, pp 17-29.
16. Veerhuis R, Van der Valk P, Jann-sen I, Zhan SS, VanNostrand WE, Eikelcnboom P: Complement activation in amyloid plaques in Alzheimer’s disease brains does not proceed further than C3. Virchows Arch Int J Pathol 1995:426:603-610.
17. Webster S, O'Barr S, Rogers J: Enhanced aggregation and ß structure of amyloid ß peptide after coincubation with ClQ. J Neurosci Res 1994; 39:448-456.
18. Schultz J, Schaller J, McKinley M, Bradt B, Cooper N, May P, Rogers J: Enhanced cytotoxicity of amyloid ß-pcptide by a complement dependent mechanism. Neurosci Lett 1994; 175:99-102.
19. McGeer PL, Itagaki S, Tago H, McGeer EG: Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987;79: 195-200.
20. Haga S, Akai K, Ishii T: Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain: An immuno-histochemical study using a novel monoclonal antibody. Acta Neuro-pathol 1989;77:569-575.
21. Wisniewski H, Wegiel J, Strojny P, Wang K-C, Kim K-S, Burragc T: Ul-trastructural morphology and im-munocytochemistry of beta amyloid classical, primitive and diffuse plaques; in Ishii T (ed): Frontiers of Alzheimer Research. Amsterdam, Elsevier, 1991, pp 99-108
22. Giulian D, Li J, Lcara B, Kcenen C: Phagocytic microglia release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture. Neurochem Int 1994;25:227-233.
23. Mackenzie IRA, Hao CH, Munoz DG: Role of microglia in senile plaque formation. Neurobiol Aging 1995;16:790-796.
24. McGeer PL, McGccr E, Rogers J, Sibley J: Anti-inflammatory drugs and Alzheimer disease Lancet 1990;335:1037.
25. Breitncr JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC: Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 1994:44:227-232.
26. Brcitner JCS, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pcricak-Vance MA, Saunders AM: Delayed onset of Alzheimer’s disease with nonsteroidal anti-intlam-matory and histamine H2 blocking drugs. Neurobiol Aging 1995:16: 523-530.
27. Andersen K, Launer LJ, Ott A, Hoes AW, Bretelcr NMB, Hofman A: Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam study. Neurology 1995:45:1441-1445.
28. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
29. Lucca U, Tettamanti M, Forloni G, Spagnoli A: Nonsteroidal Antiinflammatory Drug Use in Alzheimer's Disease. Biol Psychiatry 1994; 36:854-856.
30. Holstein J, Chatellier G, Piettc F, Moulias R: Prevalence of associated diseases in different types of dementia among elderly institutionalized patients: Analysis of 3447 records. J Am Gcriatr Soc 1994:42:972-977.
31. Rogers J, Kirby LC, Hcmpelman SR, Berry DL, McGeer PL, Kasz-niak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F: Clinical trial of indomcthacin in Alzheimer’s disease. Neurology 1993:43:1609-1611.
32. Sapolsky RM, McEwen BS: Stress, glucocorticoids and their role in degenerative changes in the aging hippocampus; in Crook T, Bartus R, Ferris S, et aL, (eds): Treatment Development Strategies for Alzheimer’s Disease. New Canaan, Mark Powley Associates, 1986, pp 151-172.
33. Sapolsky RM: A mechanism for glucocorticoid toxicity in the hippocampus: Increased neuronal vulnerability to metabolic insults. J Neurosci 1985;5:1228-1232.
34. Sapolsky RM, Pulsinclli WA: Glucocorticoids potentiate ischemic injury to neurons: Therapeutic implications. Science 1985,229:1397-1400.
35. Sapolsky RM, Uno H, Rebert CS, et al.: Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 1990; 10:1897-1902.
36. Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Rayn T, Davis KL: A pilot study of prednisone in Alzheimer’s disease. Dementia 1996;7:201-206.
37. Altstiel LD, Lawlor B, Mohs R, Schmeidler J, Dalton A, Mehta P, Davis K: Elevated alpha-1-antichy-motrypsin serum levels in a subset of nondemcnted first-degree relatives of Alzheimer’s disease patients. Dementia 1995;6:17-20.
38. Matsubara E, Hirai S, Amari M, Shoji M, Yamaguchi H, Okamoto K, Ishiguro K, Harigaya Y, Waka-bayashi W: Alpha-1-antichymotryp-sin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990;28:561-567.
39. Brugge K, Katzman R, Hill LR, Hansen LA, Saitoh T: Serological ai-antichymotrypsin in Down's syndrome and Alzheimer's disease. Ann Neurol 1992;32:193-197.
40. Hinds TR, Kukull WA, VanBelle G, Schellenberg GD, Villacrcs EC, Larson EB: Relationship between serum al-antichymotrypsin and Alzheimer’s disease. Ncurobiol Aging 1994;15:21-27.
41. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-1364.
42. Morris JC: The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43: 2412-2414.
43. Giulian D, Robertson C: Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann Neurol 1990;27:33-42.
44. HERA Study Group: A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA Study. Am J Med 1995;98:156-168.
45. Mullins JF, Watts FL, Wilson CJ: Plaquenil in the treatment of lupus erythematosus. J Am Med Assoc 1956;161:879-888.
46. Popert AJ, Mcijers KAE, Sharp J, Bier F: Chloroquine diphosphate in rheumatoid arthritis: A controlled trial. Ann Rheum Dis 1961:20:18.
47. Hamilton EBD, Scott JT: Hydroxychloroquine sulfate (plaquenil) in the treatment of rheumatoid arthritis. Arthritis Rheum 1962;5:502.
48. Bell C: Hydroxychloroquine sulfate in rheumatoid arthritis: Long term response rate and predictive parameters. Am J Med 1983;75(suppl):46-51.
49. DcDuve C, DeBarsy T, Poole B, Trouet A, Tulkens P, vanHoof F: Lysosomotropic agents. Biochcm Pharmac 1974;23:2495-2531.
50. Golde TE, Estus S, Younkin LH, Sclkoe DJ, Younkin SG: Processing of the amyloid precursor for potentially amyloidogenic derivatives. Science 1992; 155:728.
51. Caporaso GL, Gandy SE, Buxbaum JD, Greengard P: Chloroquine inhibits intracellular degradation but not secretion of Alzheimer ß/A4 amyloid precursor protein. Proc Natl Acad Sei USA 1992,89:2252-2256.
52. Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ: Targeting of cell-sur-face ß-amyloid precursor protein to lysosomes: Alternative processing into amyloid-bearing fragments. Nature 1992;357:500-503.
53. Tsuzuki K, Fukatsu R, Takamuru Y, Fujii N, Takahata N: Potentially amyloidogenic fragment of 50 kDa and intracellular processing of amyloid precursor protein in cells cultured under leupcptin. Brain Res 1994;659:213-220.
54. Wallace SL: ColchicinE, Semin Arthritis Rheum 1974;3:369-381.
55. Grinde B, Seglcn PO: Role of microtubuli in lysosomal protein degradation. Hoppe-Seyler’s Z Physiol Chem 1981;362:549-556.
56. Pesante EL, Axline SG: Colchicine effects on lysosomal enzyme induction and intracellular degradation in the cultivated macrophage. J Exp Med 1976;141:1030-1046.
57. Zemer D, Livneh A, Langevitz P: Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med 1992; 116:426.
58. Zemer D, Pras M, Sohar E, Modon M, Cabili S, Gafni J: Colchicine in the prevention and treatment of amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314: 1001-1005.
59. Shirahama T, Cohen AS: Blockage of amyloid induction by colchicine in an animal model. J Exp Med 1974;140:1102-1107.
60. Kisilevsky R, Boudreau L, Foster D: Kinetics of amyloid deposition. II, The effects of dimethylsulfoxide and colchicine therapy. Lab Invest 1983; 48:60-67.
61. Games D, et al: Development of neuropathology similar to Alzheimer's disease in transgenic mice over-expressing the 717V-F p-amyloid precursor protein. Nature 1995;373: 523-527.
62. Fagarasan MO, Aisen PS: 11-1 and anti-inflammatory' drugs modulate AP cytotoxicity in PC 12 cells. Brain Res 1996;723:231-234.
63. Aisen PS, Marin D, Fusco M, Baruch B, Ryan T, Davis KL: A pilot study of colchicine in Alzheimer’s disease. Alzheimer’s Res 1996; in press.